Ruben R. Plentz, Brigitte Schlegelberger, Peer Flemming, Michael Gebel, Hans Kreipe, Michael P. Manns, K. Lenhard Rudolph, Ludwig Wilkens – 22 August 2005 – Chromosomal instability (CIN) leads to an increase in aneuploidy and chromosomal aberrations in human hepatocellular carcinoma (HCC). Telomere shortening appears as one mechanism fostering the development of CIN. Whether telomere shortening correlates to specific genetic changes that characterize a certain type of cancer has yet to be established.

Timothy M. Pawlik, Eddie K. Abdalla, Melanie Thomas, Mark S. Roh, Gregory Y. Lauwers, Dario Ribero, Ronnie T. Poon, Jacques Belghiti, David M. Nagorney, Jean‐Nicolas Vauthey – 22 August 2005

Darius Moradpour, Volker Brass, Francois Penin – 22 August 2005 – Hepatitis C virus (HCV) is a human pathogen affecting nearly 3% of the world's population. Chronic infections can lead to cirrhosis and liver cancer. The RNA replication machine of HCV is a multi‐subunit membrane‐associated complex. The nonstructural protein NS5A is an active component of HCV replicase, as well as a pivotal regulator of replication and a modulator of cellular processes ranging from innate immunity to dysregulated cell growth.

Anna Glantz, Hanns‐Ulrich Marschall, Lars‐Åke Mattsson – 22 August 2005

Florence Wong – 22 August 2005

Frank A. Anania – 22 August 2005

Niels G. Venneman, Karel J. van Erpecum – 22 August 2005

Andres T. Blei – 22 August 2005

Tracy Chen, Linda L. Pearce, Jim Peterson, Detcho Stoyanovsky, Timothy R. Billiar – 22 August 2005 – Nitric oxide (NO) can be either cytoprotective or cytotoxic in hepatocytes, depending on conditions within the cell. We hypothesized that redox status is a determinant of NO effects on cell viability.

Yves Horsmans, Thomas Berg, Jean‐Pierre Desager, Tobias Mueller, Eckart Schott, Simon P. Fletcher, Kevin R. Steffy, Lisa A. Bauman, Bradley M. Kerr, Devron R. Averett – 22 August 2005 – Immune‐based therapy is the mainstay treatment for chronic hepatitis C virus (HCV) infection but causes multiple side effects and achieves durable viral clearance in only approximately 50% of patients. Most new investigational anti‐HCV compounds are direct‐acting antivirals for which durability of response and risk of viral mutations and resistance are not yet known.